BioNexus Gene Lab Corp.

BGLC

US0906282076

Healthcare Facilities & Services

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.5935 ^USD	+0.15%		-1.05%	+11.98%

Apr. 16	BioNexus Gene Lab Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 29	BioNexus Gene Lab Corp. Provides Information to Shareholders	CI

BioNexus Gene Lab Corp. has filed an IPO in the amount of $17.25 million.

February 14, 2023 at 12:00 am EST

BioNexus Gene Lab Corp. has filed an IPO in the amount of $17.25 million.

Security Name: Common Stock
Security Type: Common Stock

Latest news about BioNexus Gene Lab Corp.

BioNexus Gene Lab Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 16	CI
BioNexus Gene Lab Corp. Provides Information to Shareholders	Feb. 29	CI
Certain Common Stock of BioNexus Gene Lab Corp. are subject to a Lock-Up Agreement Ending on 18-JAN-2024.	Jan. 17	CI
Soo Kow Lai Provides Information to Shareholders of BioNexus Gene Lab Corp	Jan. 17	CI
BioNexus Gene Lab Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 20	CI
Bionexus Gene Lab Corp. Announces Resignation of Wei Li Leong as Chief Financial Officer	Nov. 03	CI
BioNexus Gene Lab Names Chi Yuen Leong as CEO	23-10-16	MT
BioNexus Gene Lab Corp. Appoints Mr. Chi Yuen Leong as the Chief Executive Officer	23-10-16	CI
BioNexus Gene Lab Corp. Appoints Mr. Chi Yuen Leong as A Director	23-10-16	CI
BioNexus Gene Lab Corp. Announces Resignation of Sook Keng Yeoh as Chief Executive Officer	23-10-11	CI
BioNexus Gene Lab Corp. Announces Resignation of Sook Keng Yeoh as Board of Directors	23-10-11	CI
BioNexus Gene Lab Corp. Announces Executive Changes	23-09-07	CI
Top Premarket Gainers	23-08-23	MT
BioNexus Gene Lab Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-16	CI
BioNexus Gene Lab Raises $5.8 Million from Public Share Offering	23-07-24	MT
BioNexus Gene Lab Corp.(NasdaqCM:BGLC) added to NASDAQ Composite Index	23-07-24	CI
Top Midday Gainers	23-07-21	MT
Wall Street Set to Open Higher, Investors Look to End Week on Positive Note	23-07-21	MT
Investors Look to Close Week on Positive Note as US Futures See Mixed Performance Premarket Friday	23-07-21	MT
Top Premarket Gainers	23-07-21	MT
BioNexus Gene Lab Corp. has completed an IPO in the amount of $5 million.	23-07-21	CI
BioNexus Gene Lab Shares Fall in Nasdaq Debut	23-07-20	MT
BioNexus Gene Lab Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
BioNexus Gene Lab Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
BioNexus Gene Lab Corp. has filed an IPO in the amount of $17.25 million.	23-02-14	CI

BioNexus Gene Lab Corp., through its wholly owned subsidiary, Chemrex Corporation Sdn. Bhd., focuses on the wholesale of chemical raw material products. The Company is engaged in the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. The Company is also engaged in the business of developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. Its non-invasive blood screening tests analyze changes in ribonucleic acid (RNA) to detect the risk potentiality of approximately 11 different diseases. It offers a range of fiberglass reinforced plastic (FRP) products, which include Polyester Resin SHCP 268, Polyester Resin 9509 and Polyester Resin 2802. The FRP and other raw materials it offers are used to produce a variety of goods, including handrails, bench tops, cleanroom panels, and covers for various instruments used in manufacturing.

Sector

Healthcare Facilities & Services

More about the company

Income Statement Evolution

More financial data

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
BIONEXUS GENE LAB CORP.	+11.98%	10.49M
SONIC HEALTHCARE LIMITED	-17.24%	8.25B
RADNET, INC.	+39.20%	3.58B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-39.11%	2.46B
SYNLAB AG	-8.06%	2.46B
DR. LAL PATHLABS LIMITED	-7.35%	2.38B
FLEURY S.A.	-19.01%	1.55B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-40.66%	1.21B
METROPOLIS HEALTHCARE LIMITED	+7.56%	1.11B
ADICON HOLDINGS LIMITED	-14.72%	1.03B